Clinical trials
Steatohepatitis clinical trials
Below are recruiting steatohepatitis clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT07660848RecruitingPhase 2
A study of two new injections for fatty liver disease with MASH
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–75 - NCT06528314RecruitingPhase 3
Efruxifermin for NASH-related cirrhosis
This study tests a new medication called efruxifermin for people with cirrhosis (liver scarring) caused by NASH, a type of fatty liver disease. The goal is to see if the drug can help improve liver health and prevent further damage.
Birmingham, AlabamaAges 18–80 - NCT07288138RecruitingPhase 2
Study of a New Drug for MASH (Fatty Liver Disease)
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Chandler, ArizonaAges 18–75 - NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80 - NCT07491458RecruitingPhase 2
Study of HU6 versus placebo for adults with MASH
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Chandler, ArizonaAges 30 years+ - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT06575400RecruitingPhase 1
Testing tolerance of BI 3804379 in healthy people and MASH patients
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
EdegemAges 18–65 - NCT07188220Recruiting
Understanding patient views on fatty liver disease study
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
BarcelonaAges 18–75 - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07701993RecruitingPhase 3
Testing efimosfermin for MASH with compensated cirrhosis
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Miami, FloridaAges 18–75 - NCT07704892RecruitingPhase 3
Study of efimosfermin for adults with cirrhosis from MASH
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
Miami, FloridaAges 18–75 - NCT06419374RecruitingPhase 3
Testing a new drug for liver scarring from MASH
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
Birmingham, AlabamaAges 18–75 - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT03587831Recruiting
Weight-loss surgery plus lifestyle changes for fatty liver disease
This trial studies whether vertical sleeve gastrectomy (a type of weight-loss surgery) plus lifestyle coaching works better than another planned approach to improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It may help people reduce liver fat and inflammation, but you must be willing to follow study visits and possible random assignment.
San Francisco, CaliforniaAges 30–70 - NCT04697810RecruitingPhase 2
Test drug namodenoson for non-alcoholic fatty liver inflammation
This Phase 2 trial tests whether namodenoson can improve non-alcoholic steatohepatitis (NASH), a type of fatty liver inflammation. You may need two liver biopsies to see whether liver changes improve over time.
Banja LukaAges 18 years+ - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Chandler, ArizonaAges 18–75 - NCT05526144RecruitingPhase 2
Thyroid hormone treatment for fatty liver in Veterans
This trial tests whether thyroid hormone can improve nonalcoholic steatohepatitis (fatty liver with inflammation) in Veterans. You may be asked to have a medically needed liver biopsy, and the study also focuses on safety in people with related conditions like diabetes and heart risks.
Columbia, MissouriAges 18–75 - NCT05720663Recruiting
Predicting liver outcomes in fatty liver cirrhosis
This study looks at how to predict future outcomes in adults who have fatty-liver disease (NAFLD) that has progressed to cirrhosis. It may help doctors better estimate risk and plan care, using information from liver tests and scans.
Rochester, MinnesotaAges 18 years+ - NCT05821010RecruitingPhase 2
Synbiotics and fecal transplant for non-alcoholic liver inflammation
This Phase 2 study tests whether taking special gut-helping products (synbiotics) and/or a fecal microbiota transplant can improve non-alcoholic steatohepatitis (NASH), a type of liver inflammation. It may help by changing gut bacteria that may affect liver health, but you must meet specific safety and medical criteria.
Amsterdam, North HollandAges 18–75 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT06569524RecruitingPhase 2
A new drug for NASH with liver scarring
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Lu'an, AnhuiAges 18–75
Hear when a new Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for steatohepatitis?
- Yes. Clin2 currently lists 95 recruiting steatohepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a steatohepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a steatohepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.